September 23, 2008 -- Mymetics Corporation now Blue Sky registered in 44 States - [Download]

NYON, Switzerland, September 23, 2008 -- Mymetics Corporation (OTCBB: MYMX), announced today that its common stock has been Blue Sky registered for trading in 44 US States with fully compliant filings submitted and awaiting imminent approval for the remaining (MI, MO, MN, NC, ND, TX) states. The company information is available via Standard & Poor's Market Access Program, and Standard & Poor's Advisor Insight. Standard & Poor's Advisor Insight is an Internet-based research engine used by more than 100,000 investment advisors and a public version of the site is available at www.advisorinsight.com.

In addition, information about companies in Standard & Poor';s Market Access Program will be available via S&P's Stock Guide database, which is distributed electronically to virtually all major quote vendors. As part of the program, a full description of Mymetics Corporation will also be published in the Daily News section of Standard Corporation Records, a recognized securities manual for secondary trading in approximately 38 states under their Blue Sky Laws.

Mymetics have further contracted with BlueSkyMLS www.blueskymls.com to provide registration in states not covered by the S&P Market Access Program in order to complete their US coverage.

About Mymetics Corporation
Mymetics' primary objective is to develop vaccines and therapies to prevent and treat the effects of certain retroviruses and other infectious diseases, including the human immunodeficiency virus, or HIV, the virus that leads to acquired immunodeficiency syndrome, or AIDS. Mymetics has also recently acquired from a close scientific partner an advanced malaria vaccine project currently in phase Ib clinical trial. Additional applications of Mymetics's research include potential treatments and/or vaccines for human oncoviral leukemias, multiple sclerosis, and organ transplantation.

SOURCE  Mymetics Corporation

• September 23, 2008 -- Mymetics Corporation now Blue Sky registered in 44 States - [Download]
• September 16, 2008 -- Successful Results for Mymetics Corporation’s Mucosal HIV/AIDS vaccine ViralChallenge significantly exceeds expectations - [Download]
• August 25, 2008 -- Mymetics Corporation Information to be Available Through Standard & Poor's Market Access Program - [Download]
• August 19, 2008 -- Mymetics Corporation Files SEC Form 10-Q Quarterly Report - [Download]
• July 31, 2008 -- Letter to the Shareholders - [Download]
• May 19, 2008 -- Mymetics Corporation Acquires Preventive Malaria Vaccine From Pevion Biotech AG (Switzerland) - [Download]
• March 05, 2008 -- Mymetics Corporation Hires the Investor Relations Group - [Download]
• February 14, 2008 -- MA European Healthcare Consortium, including MYMETICS Corporation, awarded €7.50 Million grant - [Download]
• June 29, 2007 -- Mymetics Expands Board of Directors with the Addition of Dr. Thomas Staehelin - [Download]
• June 07, 2007 -- Mymetics' HIV Vaccine Demonstrates First-Ever Production of Mucosal Neutralizing IgA Antibodies in Non-human Primate Model - [Download]
• March 29, 2007 -- Mymetics' HIV Vaccine Achieves Research Breakthrough, Eliciting Protective Antibody Response in Mucosal Tissues of Non-Human Primate Model - [Download]
• March 21, 2007 -- Mymetics Resolves Credit Facility and Litigation with MFC Merchant Bank - [Download]
• March 09, 2006 -- NIH Plan to test HIV-AIDS Vaccine - [Download]
• January 27, 2005 -- Stanley Plotkin joins board - [Download]
  
• December 17, 2004 -- NIH Agreement - [Download]
  
• October 25, 2004 -- Equity Funding Agreement - [Download]
  
• December 09, 2002 -- Presentation CROI Boston [Download]
  
• December 04, 2002 -- GP36 presentation [Download]
  
• September 25, 2002 -- US Patent granted [Download]
  
• September 25, 2002 -- ICAAC presentation 2 [Download]
  
• September 19, 2002 -- New management & SAB [Download]
  
• August 13, 2002 -- ICAAC Presentation [Download]